RAW MATERIALS FOR MEDICAL TEXTILES

1. RAW MATERIALS FOR MEDICAL TEXTILES 18.11.2010

2. Presentation Covers.. • Global Fibre Scenario • Fibres for Technical Textiles • Classification of Medical Textiles • Fibres for Medical Textiles • Challenges in Meditech Growth in India • Recommendations

3. Global Fibre Production Scenario Mn T – In Million Tons All Fibre 78 Million T Natural 32 Mn T 41% Manmade 46 Mn T 59% Wool 1 Mn T 2% Silk 0.15 Mn T 0.2% Cotton 24 Mn T 31% Jute/Ramie/Hemp 5.9 Mn T 8% Synthetics 43 Mn T 55% Cellulosic # 3.23 Mn T 4% Polyester 31 Mn T 39% Nylon 3.5 Mn T 5% Acrylic 1.91 Mn T 2% Olefin 6 Mn T 8% Others 1 Mn T 1% Tow (Acetate/ Viscose) 0.69 MnT 0.9% Staple (Viscose) 2.13 Mn T 2.7% # Filament (Acetate, Viscose, Cupro) 0.41 Mn T 0.5% Note : CAGR (2001 – 08) : 3.26% as per Fibre Organon Based on Average Production as on 2008

4. Fibres and their stake in Meditech * Source: World Fibre Report – YnFx, D&B Research

5. MMF - India 2nd Largest Producer, but …. • India’s total production of MMFs was 3.5 billion kg while global was 41 billion kg in 2007. • There is huge gap between China and India’s production • Ex- PSF – China- 76.6 / India 8.5 % - PFY – China 80.4 / India – 10.3% • - VSF – China – 63 / India 10.2 % • - Cotton – China – 7 / India 5.1 mil Tons (FY10) [in consumption china – 10.6 / India 4.2 mil Tons] * Source: World Fibre Report – YnFx, D&B Research

6. Fibres For Technical Textiles Fully available Mostly available Not available

7. Classification of Medical Textiles

8. Fibre /Fabric/Application- Nonimplanatable “Used for external applications and may or may contact with skin”

9. Fibre /Fabric/Application- Healthcare/Hygiene “Used either in the operation theatre or in the hospital wards for hygiene, care and safety of the staff and patients”

10. Fibre /Fabric/Application- Implantable “Used in effecting repair to the body whether it is wound closure (sutures) or replacements Surgery like vascular grafts, artificial ligaments”

11. Fibre /Fabric/Application- Extracorporeal “Used as mechanical organs that for blood purification and include artificial kidney, the artificial liver and the mechanical lung”

12. Uniqueness of Fibres used in Medical Textiles • Pure and Hygienic • Bio – degradable • Fast & High absorbency • Excellent Wicking performance • Barrier to percolation • Good Insulation • High Strength • Low Lint • Good thermal stability • Soft feel • Excellent drape ability • Breathability • Static Dissipation • Engineered Specialties • Anti-bacterial properties • Medicinal clothings

13. Challenges in Meditech Growth • India’s dominating fibre position supports the growth of medical textiles in India and exports of domestically produced medical textiles • As a consuming Hub • As a manufacturing Hub • Technology for production of most of the specialityfibres is available, but due to lack of demand, the production is negligible. Eg. – Anti Bacterial PSF/VSF • Hitechfibre technologies are available glogally, but needs domestic demand to make the investments workable • The main volume growth driver in Meditech is the Non-implantable segment which includes surgicals & healthcare/hygiene products. China leads in production capacities, while India has just arrived with considerably smaller capacities in organized sectors • Lack of standards and awareness among users is hindering the growth rate of Indian meditech industry

14. Challenges in Meditech Growth Contd.. Short Term Commercial Challenges Indian fibre producers still make available fibre and offer better prices

15. Recommendations • Marketing Efforts • Benefits of good products need to be percolated more effectively with user industry • Collaboration between fibre manufacturer and medi-product producer is essential • Encourage conversion facilities for nonwoven medi-products • Collective efforts of govt., research institutes and industry to cover the gap in awareness of user industry and standardization • Participation of manufacturers in international forums to promote Indian medi-products and establish India as a manufacturing hub

16. Recommendations • Product Standardization Effort • Standards for meditech products needs to be developed in harmony with EU/US particularly for healthcare • Center of excellence SITRA and its support services need to be extended to various regions • Nonwoven products have no mention in the product standards. For non-implantables, BIS standards as well as IP only mentions of woven products, whereas nonwovens are taking major share worldwide • All govt. tenders should have woven as well as nonwovens as product options for non-implantables

17. Recommendations • Government Levies • Labelling to be made mandatory and promotion of label is desired • DEPB / DD needs to cover the duty paid, which is absent for most of the new meditech products • To curb the sub-standard products and promote the local meditech industry, even mis-declaration as off-lot papers many times. Checks and controls are required • To promote the usage of new technology nonwoven products, the excise duty needs to be made at par with the woven products

18. THANK YOU